These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30933694)

  • 1. Coronary atheroma regression and adverse cardiac events: A systematic review and meta-regression analysis.
    Bhindi R; Guan M; Zhao Y; Humphries KH; Mancini GBJ
    Atherosclerosis; 2019 May; 284():194-201. PubMed ID: 30933694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherosclerotic Coronary Plaque Regression and Risk of Adverse Cardiovascular Events: A Systematic Review and Updated Meta-Regression Analysis.
    Iatan I; Guan M; Humphries KH; Yeoh E; Mancini GBJ
    JAMA Cardiol; 2023 Oct; 8(10):937-945. PubMed ID: 37647074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HbA1c, Coronary atheroma progression and cardiovascular outcomes.
    Dykun I; Bayturan O; Carlo J; Nissen SE; Kapadia SR; Tuzcu EM; Nicholls SJ; Puri R
    Am J Prev Cardiol; 2022 Mar; 9():100317. PubMed ID: 35112095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials.
    D'Ascenzo F; Agostoni P; Abbate A; Castagno D; Lipinski MJ; Vetrovec GW; Frati G; Presutti DG; Quadri G; Moretti C; Gaita F; Zoccai GB
    Atherosclerosis; 2013 Jan; 226(1):178-85. PubMed ID: 23206978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome.
    Nicholls SJ; Hsu A; Wolski K; Hu B; Bayturan O; Lavoie A; Uno K; Tuzcu EM; Nissen SE
    J Am Coll Cardiol; 2010 May; 55(21):2399-407. PubMed ID: 20488313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between changes in coronary atherosclerotic plaque burden measured by intravascular ultrasound and cardiovascular disease outcomes: a systematic literature review.
    Forbes C; Quek RG; Deshpande S; Worthy G; Ross J; Kleijnen J; Gandra SR; Kassahun H; Wong ND; Nicholls SJ
    Curr Med Res Opin; 2016 Jun; 32(6):1143-50. PubMed ID: 26949994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS.
    Puri R; Nissen SE; Menon V; Shao M; Hsu A; Bakris GL; Kastelein JJ; Williams B; Armbrecht J; Brunel P; Kataoka Y; Nicholls SJ
    Atherosclerosis; 2015 Dec; 243(2):553-9. PubMed ID: 26523993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors underlying regression of coronary atheroma with potent statin therapy.
    Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Jun; 34(24):1818-25. PubMed ID: 23644179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
    Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
    JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events.
    Puri R; Wolski K; Uno K; Kataoka Y; King KL; Crowe TD; Kapadia SR; Tuzcu EM; Nissen SE; Nicholls SJ
    JACC Cardiovasc Interv; 2013 Jan; 6(1):29-35. PubMed ID: 23347860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
    Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    JACC Cardiovasc Imaging; 2014 Oct; 7(10):1013-22. PubMed ID: 25240453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of whole-heart Atherosclerosis by coronary CT and major adverse cardiovascular events.
    van Rosendael AR; Lin FY; van den Hoogen IJ; Ma X; Gianni U; Al Hussein Alawamlh O; Al'Aref SJ; Peña JM; Andreini D; Budoff MJ; Cademartiri F; Chinnaiyan K; Choi JH; Conte E; Marques H; de Araújo Gonçalves P; Gottlieb I; Hadamitzky M; Leipsic J; Maffei E; Pontone G; Raff GL; Shin S; Kim YJ; Lee BK; Chun EJ; Sung JM; Lee SE; Han D; Berman DS; Virmani R; Samady H; Stone P; Narula J; Bax JJ; Shaw LJ; Min JK; Chang HJ
    J Cardiovasc Comput Tomogr; 2021; 15(4):322-330. PubMed ID: 33451974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
    Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS; Nissen SE; Nicholls SJ
    Atherosclerosis; 2017 Aug; 263():137-144. PubMed ID: 28641153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.